BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year. Crossover investors are the most prolific backers...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

Friday’s listings added two more companies to the boffo first-day performers among 2020 NASDAQ lPOs. Of the nineteen biopharmas in the class, 16 saw share price gains on the first day, and 11 saw gains...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond its internal expertise. President Sakae Asanuma established...
BioCentury | May 13, 2020
Finance

Daily Chart: NASDAQ IPOs forge ahead

Apart from a transient slowdown, the biotech IPO market on NASDAQ has barely registered a pandemic is happening. Companies raised a combined $1.8 billion through the end of April, surpassing the same period last year,...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

Activity among biotech IPOs has reached a steady drip following a slowdown for several weeks as COVID-19’s spread roiled markets earlier this year. The latest to file for a NASDAQ listing is Pliant, a clinical...
BioCentury | May 9, 2020
Finance

Ayala becomes latest to join the year’s bumper crop of biopharma IPOs

Ayala’s public debut late Thursday adds to the more than $4 billion raised from global biopharma IPOs so far this year. This year is outpacing 2019 for total funds raised in IPOs even as investors...
BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

Small molecule CD73 inhibitor for cancer   A small molecule CD73 inhibitor from ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) has shown significant antitumor activity in vivo . ORIC-533 is slated for an IND submission in 1H21. CD73, which...
BioCentury | May 1, 2020
Finance

As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

Lyra became the latest biotech to gain value after pricing its IPO at the top of its range, signaling continued strength among the sector’s new listings in a season of volatility. The ear, nose and...
BioCentury | Apr 27, 2020
Finance

ADC renews IPO bid as first regulatory filing looms

Less than four months after new pivotal data strengthened its case for a BLA submission this year, ADC has again filed a prospectus for an IPO -- although it may be a more modest one...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
Items per page:
1 - 10 of 30
BioCentury | Aug 3, 2020
Finance

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year. Crossover investors are the most prolific backers...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

Friday’s listings added two more companies to the boffo first-day performers among 2020 NASDAQ lPOs. Of the nineteen biopharmas in the class, 16 saw share price gains on the first day, and 11 saw gains...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond its internal expertise. President Sakae Asanuma established...
BioCentury | May 13, 2020
Finance

Daily Chart: NASDAQ IPOs forge ahead

Apart from a transient slowdown, the biotech IPO market on NASDAQ has barely registered a pandemic is happening. Companies raised a combined $1.8 billion through the end of April, surpassing the same period last year,...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

Activity among biotech IPOs has reached a steady drip following a slowdown for several weeks as COVID-19’s spread roiled markets earlier this year. The latest to file for a NASDAQ listing is Pliant, a clinical...
BioCentury | May 9, 2020
Finance

Ayala becomes latest to join the year’s bumper crop of biopharma IPOs

Ayala’s public debut late Thursday adds to the more than $4 billion raised from global biopharma IPOs so far this year. This year is outpacing 2019 for total funds raised in IPOs even as investors...
BioCentury | May 2, 2020
Translation in Brief

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

Small molecule CD73 inhibitor for cancer   A small molecule CD73 inhibitor from ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) has shown significant antitumor activity in vivo . ORIC-533 is slated for an IND submission in 1H21. CD73, which...
BioCentury | May 1, 2020
Finance

As market’s upbeat April draws to close, Lyra becomes latest biotech IPO to surge

Lyra became the latest biotech to gain value after pricing its IPO at the top of its range, signaling continued strength among the sector’s new listings in a season of volatility. The ear, nose and...
BioCentury | Apr 27, 2020
Finance

ADC renews IPO bid as first regulatory filing looms

Less than four months after new pivotal data strengthened its case for a BLA submission this year, ADC has again filed a prospectus for an IPO -- although it may be a more modest one...
BioCentury | Apr 24, 2020
Finance

Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors...
Items per page:
1 - 10 of 30